AcelRx presents positive findings from Phase 2 study on ARX-04 AcelRx presented additional detail from the Phase 2 dose-finding study of ARX-04, an investigational single-dose sublingual sufentanil NanoTab for moderate-to-severe acute pain. Patients treated with the 30 mcg dose of sufentanil showed a rapid onset of action with a statistically significant beneficial difference in pain relief and pain intensity seen at 30 minutes after dosing compared to placebo. In addition, patient global assessment of the 30 mcg dose at 12 hours was superior to placebo with 43.6% vs. 5.0% of the patients responding good or excellent for overall pain control. The 20 mcg dose was not significant for either endpoint.
News For ACRX From The Last 14 Days
Check below for free stories on ACRX the last two weeks.
AcelRx reports Q4 adjusted EPS (18c), consensus (17c) Reports Q4 revenue $27.6M, may not compare to consensus $4.93M. During the fourth quarter of 2013, AcelRx received a $30M upfront payment from Grunenthal GmbH associated with the Zalviso commercialization agreement in the EU and Australia, of which $27.4M was recognized as revenue in the quarter.